Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of NYSE BTX opened at $1.92 on Thursday. The stock has a market capitalization of $112.95 million, a PE ratio of -0.85 and a beta of 4.61. The business has a fifty day moving average price of $1.90 and a two-hundred day moving average price of $1.98. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Further Reading

• Five stocks we like better than Brooklyn ImmunoTherapeutics
• Bank Stocks – Best Bank Stocks to Invest In
• Food Processing Company Stock Gets Fried by Recall: Time to Buy
• 3 Grocery Stocks That Are Proving They Are Still Essential
• Entertainment Stock Offers A Rare and Tempting Entry Opportunity
• Stock Ratings and Recommendations: Understanding Analyst Ratings
• Will China’s Interest Rate Cuts Ignite a Rally for This Stock?

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.